Product Code: SR112023A4085
Abstract
The global actinic keratosis treatment market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.3% during 2022-2028.
Actinic keratosis, also known as solar keratosis, refers to a skin condition that develops on the sun-exposed areas of the body. It causes rough, scaly patches to appear on the hands, arms, lips, scalp, and other body parts that can further develop into a skin cancer called squamous cell carcinoma. Some of the commonly used treatments to remove actinic keratosis include cryotherapy, curettage, laser therapy, and photodynamic therapy. At present, the considerably expanding healthcare infrastructure and increasing need for preventive strategies for cancer are positively influencing the demand for actinic keratosis treatment worldwide.
Actinic Keratosis Treatment Market Trends:
The increasing prevalence of actinic keratosis due to ozone layer depletion and excessive sun exposure represents one of the key factors fueling the growth of the market. Additionally, the rising incidences of cancer, coupled with the escalating demand for minimally invasive (MI) procedures, is strengthening the market growth. Furthermore, leading manufacturers are introducing medications for the treatment of actinic keratosis in the form of cream and gel, which is impelling the market growth. Apart from this, numerous public and private groups are focusing on conducting campaigns to generate awareness about available treatments for actinic keratosis across the globe. This, along with significant investments in the research and development (R&D) activities to develop novel therapies with improved efficacy, convenient dosage, and reduced costs, is creating a favorable market outlook. The market is also driven by the introduction of topical treatment that reduces the risk of scarring. This treatment is also used for treating a wide area of visible and invisible lesions on the skin. Besides this, favorable reimbursement policies are anticipated to fuel the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global actinic keratosis treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, drug type and distribution channel.
Breakup by Type:
Prescription
OTC
Breakup by Drug Type:
Fluorouracil
Imiquimod
Diclofenac
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Almirall SA, Bausch Health Companies Inc., Biofrontera Inc., BioLineRx Ltd., Cipher Pharmaceuticals Inc, Galderma SA, Hill Dermaceuticals Inc., LEO Pharma A/S and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
- How has the global actinic keratosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global actinic keratosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global actinic keratosis treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Actinic Keratosis Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Prescription
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 OTC
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 Fluorouracil
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Imiquimod
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Diclofenac
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Drug Stores and Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 3M Company
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Almirall SA
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bausch Health Companies Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Biofrontera Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 BioLineRx Ltd.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Cipher Pharmaceuticals Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Galderma SA
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Hill Dermaceuticals Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 LEO Pharma A/S
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Sun Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis